Clinical TrialMay 11, 2026, 04:18 PM
CG Oncology to Present Phase 2 Trial Results at AUA 2026
AI Summary
CG Oncology, Inc. announced its participation in the American Urological Association (AUA) 2026 Annual Meeting, where it will present the first results from its CORE-008 Cohort CX Phase 2 Trial. This trial evaluates an intravesical combination therapy for High-Risk BCG-Exposed and BCG-Unresponsive non-muscle invasive bladder cancer (NMIBC) patients. The company will have both poster and podium presentations on May 15 and 16, respectively. Additionally, grant recipients of the CG-SUO-CTC NMIBC Research Fellowship will present their research at the SUO 2026 Annual Meeting at the AUA.
Key Highlights
- CG Oncology to present first results from CORE-008 Cohort CX Phase 2 Trial.
- Trial evaluates intravesical combination therapy for High-Risk BCG-Exposed and BCG-Unresponsive NMIBC.
- Presentations scheduled for the American Urological Association (AUA) 2026 Annual Meeting, May 15–18.
- Poster Presentation on May 15, 2026, from 3:30 – 5:30 PM ET.
- Podium Presentation at SUO 2026 Annual Meeting at AUA on May 16, 2026, from 4:25–4:30 PM ET.
- Grant recipients of the annual CG-SUO-CTC NMIBC Research Fellowship will also present their research.
- CG Oncology will be exhibiting at booth #3051 at the AUA Annual Meeting.
Price Impact
More from CGON